Kerala Daily

Alopecia Clinical Trial Insight, Pipeline Assessment, Companies, Emerging Drugs by DelveInsight

 Breaking News
  • No posts were found

Alopecia Clinical Trial Insight, Pipeline Assessment, Companies, Emerging Drugs by DelveInsight

September 28
21:15 2020
Alopecia Clinical Trial Insight, Pipeline Assessment, Companies, Emerging Drugs by DelveInsight

Alopecia Pipeline Insight, 2020”

(Albany, US) DelveInsight has launched a new report on “Alopecia Pipeline Insight, 2020”.

 

Alopecia Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Alopecia market. A detailed picture of the Alopecia pipeline landscape is provided, which includes the disease overview and Alopecia treatment guidelines.

The assessment part of the report embraces in-depth Alopecia commercial assessment and clinical assessment of the Alopecia pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alopecia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Some of key companies are-

  • Merck Pharma Co.
  • Johnson & Johnson Co. 
  • Samumed
  • And Many Others

 

Request for free sample report: https://www.delveinsight.com/sample-request/alopecia-pipeline-insight

 

Name of drugs covered which are given below-

  • Propecia (finasteride)
  • Rogaine (Minoxidil)
  • SM04554
  • And Many Others

 

 

Scope of the Report

  • The Alopecia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Alopecia across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Alopecia therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Alopecia research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Alopecia.

 

Request for free sample report: https://www.delveinsight.com/sample-request/alopecia-pipeline-insight

 

Hair loss also known as alopecia or baldness, refers to a loss of hair from part of the head or body. Typically, at least the head is involved, and the severity of hair loss can vary from a small area to the entire body.

About one-third of women experience hair loss at some time in their lives; among postmenopausal women, as many as two-thirds suffer hair thinning or bald spots. Hair loss in women often has a greater impact than hair loss does on men, because it is less socially acceptable for them. Alopecia can severely affect a woman’s emotional well-being and quality of life.

The condition occurs when white blood cells attack the cells in hair follicles, causing them to shrink and dramatically slow down hair production. It is unknown precisely what causes the body’s immune system to target hair follicles in this way.

There are different types of alopecia varying in terms of causes, severity (how much hair falls out), patterns of hair loss, the usual age it starts and body parts affected. Most of the people have alopecia areata, which is often used as an umbrella name for a spectrum (a range) of types: areata, totalis, and universalis. Because alopecia areata is a spectrum, many people had hair loss ‘in-between’ these named points. Some people found that their alopecia changed along the spectrum over time.

The extreme forms of alopecia areata are alopecia total is, which involves the loss of all head hair, and alopecia universal is, which involves the loss of all hair from the head and the body.

The main type of hair loss in women is the same as it is men.

It is called androgenetic alopecia (AGA), or female (or male) pattern hair loss. In men, hair loss usually begins above the temples, and the receding hairline eventually forms a characteristic “M” shape; hair at the top of the head also thins, often progressing to baldness. In women, androgenetic alopecia begins with gradual thinning at the part line, followed by increasing diffuse hair loss radiating from the top of the head. A woman’s hairline rarely recedes, and women rarely become bald.

Dihydrotestosterone (DHT) is the main hormone responsible for Androgenetic Alopecia in genetically susceptible individuals. DHT causes hair loss by inducing a change in the hair follicles. The hairs produced by the follicles affected by DHT become progressively smaller until eventually the follicles shrink completely and stop producing hair entirely.

 

Request for free sample report: https://www.delveinsight.com/sample-request/alopecia-pipeline-insight

 

Table of Contents:

1. Report Introduction

2. Alopecia 

2.1. Overview

2.2. History 

2.3. Alopecia Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Alopecia Diagnosis 

2.6.1. Diagnostic Guidelines

3. Alopecia Current Treatment Patterns

3.1. Alopecia Treatment Guidelines

4. Alopecia – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Alopecia companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Alopecia Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Alopecia Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Alopecia Late Stage Products (Phase-III)

7. Alopecia Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Alopecia Discontinued Products

13. Alopecia Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition 

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report? 

14. Alopecia Key Companies

15. Alopecia Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Alopecia Unmet Needs

18. Alopecia Future Perspectives

19. Alopecia Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation 

 

Request for Detailed TOC: https://www.delveinsight.com/sample-request/alopecia-pipeline-insight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/sample-request/alopecia-pipeline-insight